| 注册
首页|期刊导航|中国临床药理学杂志|托伐普坦片治疗心力衰竭伴收缩功能障碍的临床研究

托伐普坦片治疗心力衰竭伴收缩功能障碍的临床研究

胡武明 施振华 叶士勇 向贻佳 曾春来

中国临床药理学杂志2019,Vol.35Issue(7):617-619,3.
中国临床药理学杂志2019,Vol.35Issue(7):617-619,3.DOI:10.13699/j.cnki.1001-6821.2019.07.005

托伐普坦片治疗心力衰竭伴收缩功能障碍的临床研究

Clinical trial of tolvaptan tablets in the treatment of heart failure with systolic dysfunction

胡武明 1施振华 1叶士勇 1向贻佳 1曾春来1

作者信息

  • 1. 丽水市中心医院 心内科,浙江 丽水 323000
  • 折叠

摘要

Abstract

Objective To compare the clinical efficacy and safety of tolvaptan tablets and furosemide injection in the treatment of heart failure with systolic dysfunction. Methods One hundred and four patients of heart failure with systolic dysfunction were randomly divided into control group (n = 49 cases) and treatment group (n = 55 cases) . Control group received furosemide 40 mg per time, qd, intravenous bolus. Treatment group received tolvaptan 15 mg per time, qd, orally. The clinical efficacy, heart rate, pulmonary artery pressure, pulmonary capillary pressure and cardiac output, and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of treatment and control groups were 89. 09% (49 cases/55 cases) and71. 43% (35 cases/49 cases) with significant difference (P < 0. 05) .After treatment, the main indexes of treatment and control groups were compared: heart rates were (80. 15 ± 10. 04) and (84. 71 ± 9. 66) beat·min-1, pulmonary artery pressure were (21. 85 ± 4. 49) and (28. 47 ± 4. 46) mm Hg, pulmonary capillary pressure were (11. 24 ± 1. 61) and (15. 18 ± 2. 76) mm Hg, cardiac output were (1. 94 ± 0. 30) and (2. 16 ± 0. 25) L · min-1· m-2, the differences were statistically significant (all P < 0. 05) . The adverse drug reactions of treatment group were increased blood sodium, urinary frequency and dry mouth, which in control group were fatigue, thirst and muscle soreness. The total incidences of adverse drug reactions in the treatment and control groups were 12. 73% and 12. 24% without significant difference (P> 0. 05) . Conclusion Tolvaptan tablets have a definitive clinical efficacy in the treatment of heart failure with systolic dysfunction, which can effectively improve the heart rate, pulmonary artery pressure, pulmonary capillary pressure and cardiac output, without increasing the incidence of adverse drug reactions.

关键词

托伐普坦片/呋塞米注射液/心力衰竭/收缩功能障碍/安全性评估

Key words

tolvaptan tablet/furosemide injection/heart failure/systolic dysfunction/safety assessment

分类

医药卫生

引用本文复制引用

胡武明,施振华,叶士勇,向贻佳,曾春来..托伐普坦片治疗心力衰竭伴收缩功能障碍的临床研究[J].中国临床药理学杂志,2019,35(7):617-619,3.

中国临床药理学杂志

OA北大核心CSCDCSTPCD

1001-6821

访问量4
|
下载量0
段落导航相关论文